Compare DAIO & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAIO | CELU |
|---|---|---|
| Founded | 1969 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.2M | 26.5M |
| IPO Year | 2026 | 2019 |
| Metric | DAIO | CELU |
|---|---|---|
| Price | $2.62 | $0.44 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 28.4K | ★ 182.4K |
| Earning Date | 11-12-2026 | 12-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | $21,500,000.00 | ★ $26,550,000.00 |
| Revenue This Year | $3.26 | $165.42 |
| Revenue Next Year | $25.00 | $305.36 |
| P/E Ratio | ★ N/A | $11.70 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.16 | $0.46 |
| 52 Week High | $4.49 | $2.55 |
| Indicator | DAIO | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 49.79 | 25.58 |
| Support Level | $2.28 | N/A |
| Resistance Level | $2.73 | $0.83 |
| Average True Range (ATR) | 0.17 | 0.10 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 58.33 | 6.38 |
Data I/O Corp provides semiconductor programming, security provisioning, and intellectual property protection and management solutions used in electronics manufacturing with flash memory, microcontrollers, and flash memory-based intelligent devices as well as secure element devices, authentication devices and secure microcontrollers. It operates as a single segment entity, with the sole objective to design, manufacture, and sell programming solutions and Programming-as-a-Service (PaaS) to the world's various electronics manufacturers including OEMs, CMs and EMS companies. The company operate in three separate locations Redmond, Washington; Shanghai, China; and Munich, Germany.
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.